sinc
advent
first
vaccin
centuri
ago
research
tri
find
answer
common
pandem
diseas
immunotherapi
vaccin
success
manag
erad
lot
preval
diseas
associ
offtarget
respons
lack
prolong
protect
across
variabl
pathogen
strain
allergi
limit
horizon
prevent
treatment
global
preval
diseas
like
tuberculosi
aid
malaria
influenza
cancer
though
prophylact
vaccin
use
liveattenu
inactiv
pathogen
lack
respons
protect
divers
pathogen
strain
addit
nanoparticl
abil
impart
stabil
high
antigen
load
less
proteasom
degrad
antigen
subunit
small
specif
subunit
often
tend
less
immunogen
overcom
use
adjuv
produc
coimmunostimulatori
immunomodulatori
signal
side
effect
associ
convent
adjuv
individualspecif
respons
immunotoler
target
antigen
unwant
reaction
toward
selfantigen
limit
use
therefor
biocompat
nanoparticl
also
directli
use
adjuv
may
mitig
need
strong
convent
adjuv
eg
alum
anoth
reason
associ
low
subunit
immunogen
low
cellular
intern
rapid
clearanc
bodi
nanoparticl
tunabl
physicochem
properti
overcom
limit
enhanc
circul
time
bioaccumul
lymphoid
organ
effici
target
immun
cell
also
increas
crosspresent
antigenpres
cell
apc
activ
immun
system
much
lower
dose
instanc
poli
lacticcoglycol
acid
plga
base
nanoparticl
enhanc
cross
present
ovalbumin
major
histocompat
complexi
mhci
bone
marrow
deriv
primari
dendrit
cell
due
cell
stimul
lower
concentr
compar
solubl
antigen
differ
kind
nanoparticl
lipidbas
polymer
inorgan
proteinpeptidebas
extens
use
adjuv
immunogen
antigen
deliveri
vehicl
immun
activ
synthet
nanoparticl
interact
apc
structur
increas
intern
rather
function
lack
specif
bind
locat
cell
receptor
contrari
proteinbas
nanoparticl
interact
structur
function
carri
antigen
well
interact
pattern
associ
receptor
apc
nanovaccin
abil
induc
compon
human
adapt
immun
ie
cellmedi
well
antibodymedi
immun
induct
memori
respons
prolong
releas
antigen
nanoparticl
depot
caus
enhanc
stimul
long
period
time
allevi
need
frequent
booster
dose
therefor
nanovaccin
use
prophylact
therapeut
involv
administr
occurr
diseas
respect
howev
safeti
biodistribut
resid
nanoparticl
must
optim
obtain
prefer
immun
respons
toward
nanoparticlebas
vaccin
review
potenti
pro
con
nanoparticlebas
vaccin
explor
role
differ
nanovaccin
activ
variou
arm
immun
intent
abat
use
frequent
booster
dose
vaccin
tuberculosi
malaria
hiv
human
immunodefici
viru
influenza
cancer
discuss
applic
advantag
nanovaccin
variou
infecti
noninfecti
diseas
also
delin
articl
ultim
goal
vaccin
gener
safe
effici
primari
well
secondari
immun
respons
bodi
simplifi
way
primari
immun
respons
protect
bodi
potenti
damag
might
occur
first
exposur
pathogen
antigen
hand
secondari
immun
respons
compar
rapid
stronger
elicit
depend
immunolog
memori
gener
first
exposur
protect
bodi
futur
encount
epitop
nanoparticlebas
vaccin
deliveri
emerg
appeal
platform
boost
primari
well
secondari
immun
respons
bodi
multipl
mechan
nanovaccin
help
enhanc
immun
respons
nanovaccin
facilit
uptak
antigen
dendrit
cell
dc
enhanc
decor
particl
surfac
ligand
select
recogn
receptor
dc
refer
fig
exampl
ligand
includ
fc
fragment
mannos
mab
wide
explor
select
bind
fc
receptor
mannos
receptor
receptor
respect
dc
addit
effici
intern
abil
codeliv
multipleantigen
adjuv
inher
adjuv
properti
rapid
lymph
node
drainag
effici
antigen
present
dc
surfac
predomin
mechan
nanovaccin
help
increas
durat
well
magnitud
immun
respons
immun
anim
interestingli
properti
nanoparticl
substanti
engin
achiev
desir
immun
respons
develop
either
prophylact
therapeut
vaccin
design
safe
effect
nanovaccin
imper
understand
mechan
nanovaccin
activ
innat
adapt
immun
bodi
prophylact
nanovaccin
gener
administ
subcutan
intramuscularli
intranas
wherea
therapeut
vaccin
eg
cancer
treatment
inject
intraven
depend
rout
immun
nanovaccin
first
encount
immun
cell
includ
neutrophil
macrophag
dc
natur
killer
nk
cell
quickli
recogn
nanovaccin
foreign
particl
base
pathogen
associ
molecular
pattern
pamp
associ
pamp
eg
bacteri
lp
teichoic
acid
lectin
oligonucleotid
materi
carrier
nanoparticl
etc
serv
ligand
prr
eg
tolllik
receptor
tlr
ctype
lectin
receptor
clr
retino
acidinduc
genei
like
receptor
rlr
etc
abundantli
present
cell
thu
interact
pamp
prr
trigger
endocytosi
larger
particl
usual
nm
preferenti
macrophag
smaller
particl
dc
engulf
nanovaccin
macrophag
result
gradual
degrad
nanovaccin
particl
encapsul
antigen
prevent
nanovaccin
particl
engin
surviv
attack
macrophag
facilit
direct
deliveri
apc
addit
depend
type
pamp
neutrophil
macrophag
secret
varieti
cytokin
chemokin
activ
apc
besid
pamp
sever
unknown
mechan
activ
innat
immun
exampl
induct
immun
respons
potenti
adjuv
effect
glycol
acid
compon
plga
copolym
cation
liposom
eventu
secret
cytokin
chemokin
stimul
matur
activ
apc
mainli
dc
initi
strong
adapt
immun
respons
refer
fig
therapeut
nanovaccin
develop
treatment
metastat
cancer
directli
target
dc
strengthen
adapt
immun
respons
bodi
activ
dc
serv
link
innat
adapt
immun
adapt
immun
gener
two
arm
cellmedi
antibodymedi
immun
adapt
immun
respons
gener
within
day
sever
week
last
longer
essenti
type
immun
necessari
protect
prolong
immun
respons
howev
requir
differ
prophylact
therapeut
nanovaccin
instanc
strong
cellmedi
cytotox
respons
desir
case
therapeut
nanovaccin
order
effect
kill
metastat
cancer
cell
vaccin
provok
cellmedi
immun
gener
b
cell
cell
serv
neutral
pathogenantigen
simultan
stimul
bodi
develop
immunolog
memori
cmi
respons
trigger
migrat
activ
dc
follow
uptak
nanovaccin
particl
lymphat
organ
spleen
lymph
note
activ
dc
present
antigen
via
mhc
class
receptor
cytotox
lymphocyt
ctl
refer
fig
activ
ctl
elicit
strong
cmi
select
kill
target
cell
infect
alter
cell
cancer
cell
induc
apoptosi
kill
target
cell
complex
immunolog
process
attract
sever
compliment
system
cs
protein
costimulatori
molecul
therapeut
cancer
nanovaccin
preferenti
design
strengthen
ctl
respons
ex
vivo
educ
dc
via
adopt
transfer
antigen
exampl
sipuleucelt
therapeut
vaccin
approv
treatment
metastat
contract
resist
prostat
cancer
hand
activ
dc
also
present
antigen
thelper
cell
th
cell
via
mhcii
receptor
subsequ
effector
th
cell
undergo
activ
matur
lead
secret
varieti
cytokin
signal
refer
fig
depend
type
cytokin
secret
th
popul
divid
cell
cell
subset
subset
majorli
secret
proinflammatori
cytokin
eg
stimul
prolifer
ctl
strengthen
function
cmi
subset
secret
class
cytokin
eg
stimul
b
cell
prolifer
antibodymedi
immun
respons
subtl
balanc
respons
determin
overal
therapeut
prophylact
vaccin
potenti
candid
nanovaccin
case
nanovaccin
also
work
suppress
tregulatori
treg
cell
natur
suppress
activ
prolifer
effector
cell
bodi
depend
potenti
nanovaccin
gener
strong
cytokin
respons
b
cell
locat
spleen
lymph
node
get
stimul
bind
solubl
antigen
via
b
cell
receptor
bcr
activ
b
cell
popul
undergo
prolifer
germin
center
somat
hyper
mutat
b
cell
becom
specif
particular
epitop
antigen
epitopespecif
b
cell
select
clonal
select
prolifer
stage
activ
b
cell
either
differenti
antibodysecret
plasma
cell
secret
solubl
antibodi
target
antigen
remain
dormant
memori
cell
futur
encount
antigen
refer
fig
plasma
cell
shortliv
number
gradual
declin
time
correspond
antibodi
titer
case
memori
cell
b
cell
cell
gener
store
lymphat
organ
bone
marrow
sever
month
come
play
protect
bodi
reinfect
antigen
situat
memori
b
cell
quickli
prolifer
turn
antibodysecret
mainli
igg
plasma
cell
neutral
antigen
hand
memori
cell
type
serv
produc
cytokin
chemokin
signal
stimul
enhanc
cmi
antibodymedi
respons
howev
case
structur
antigen
epitop
undergon
signific
chang
due
cleavag
aggreg
refold
even
memori
cell
provid
requir
protect
although
case
primari
immun
offer
protect
howev
even
rest
disastr
therefor
booster
dose
schedul
increas
protect
booster
dose
promot
gener
popul
varieti
memori
cell
gener
booster
dose
schedul
antibodi
titer
plasma
cell
dramat
declin
allow
competit
bind
memori
cell
inject
antigen
relat
context
use
nanoparticl
help
recal
robust
immunolog
memori
even
low
dose
nanoparticl
eg
plga
base
nanovaccin
facilit
prolong
avail
intact
antigen
blood
due
sustain
releas
lead
higher
prolifer
b
cell
henc
memori
cell
also
due
small
size
nanoparticl
travel
narrow
lymphat
system
lymph
node
induc
differenti
memori
cell
exampl
demento
et
al
report
alumbas
free
antigen
liposomebas
burst
releas
carrier
mice
immun
ovaexpress
listeria
monocytogen
lmova
encapsul
plga
particl
sustainedreleas
show
highest
protect
lethal
dose
l
monocytogen
even
week
post
immun
observ
mice
immun
antigen
plga
nanoparticl
robust
popul
memori
cell
similarli
kanchan
et
al
show
encapsul
tetanu
toxoid
tt
insid
poli
lactic
acid
pla
particl
gener
long
last
primari
antibodi
respons
mice
interestingli
even
month
reexpos
anim
use
low
antigen
dose
induc
heighten
robust
b
cell
respons
nanomateri
effici
use
design
nanovaccin
enhanc
immunemodul
base
potenti
use
employ
adjuv
immunogen
nanocarri
enhanc
prolong
antigen
deliveri
properti
nanoparticl
strongli
govern
size
shape
composit
surfac
chemistri
rout
administr
play
import
role
decid
capabl
induc
inflammatori
respons
express
specif
defenserel
gene
differ
type
nanoparticl
like
protein
lipid
polym
inorgan
particl
gold
iron
carbon
silica
nanoparticl
induc
immun
stimul
discuss
adjuv
use
vaccin
enhanc
potenc
combin
mechan
adjuv
activ
innat
immun
respons
shape
trigger
adapt
immun
respons
vaccin
tradit
use
adjuv
alum
complet
freund
adjuv
combin
alum
monophosphoryl
lipid
known
form
local
depot
induc
secret
cytokin
chemokin
recruit
immun
cell
absorpt
antigen
surfac
adjuv
enhanc
antigen
uptak
present
thu
promot
antigen
transport
drain
lymph
node
activ
tlr
potenti
use
design
vaccin
adjuv
tlr
ligand
agonist
serv
potenti
immunostimulatori
molecul
tlr
activ
innat
immun
respons
identifi
pamp
signal
transcript
factor
respons
immun
respons
irf
lymphocyt
activ
codeliveri
antigen
along
tlr
ligand
promot
antigen
present
cell
via
mhcii
signal
crosspresent
activ
cell
tlr
agonist
cpg
upregul
express
mhc
class
ii
molecul
thu
enhanc
antigen
process
present
plasmacytoid
dc
nanovaccin
gener
amplifi
specif
robust
respons
compar
tradit
vaccin
despit
similar
mechan
immun
activ
exagger
immun
respons
gener
nanoparticl
associ
antigen
due
abil
specif
target
dendrit
cell
enhanc
cellular
uptak
antigen
present
moreov
nanoparticl
use
adjuv
specif
antigen
immunogen
vaccin
antigen
either
encapsul
insid
surfac
decor
nanoparticl
get
deliv
effici
refer
fig
chanc
free
antigen
may
degrad
elicit
local
immun
respons
site
administr
therefor
encapsul
free
antigen
insid
nanoparticl
prevent
degrad
provid
prolong
control
releas
target
site
control
releas
antigen
prevent
burst
respons
elimin
need
booster
dose
surfac
decor
nanoparticl
antigen
also
confer
advantag
present
antigen
cell
similar
way
present
pathogen
polyanhydridebas
nanoparticl
encapsul
antigen
administ
intranas
induc
immun
respons
persist
week
elicit
high
antibodi
respons
postvaccin
confer
longliv
protect
immun
yersinia
pesti
infect
compar
recombin
antigen
similar
nanoparticl
function
dimannos
target
macrophag
mannos
receptor
mmr
carbohydr
function
nanoparticl
enabl
sustain
releas
immunogen
day
enhanc
uptak
antigen
dendrit
cell
simultan
upregul
costimulatori
molecul
clr
cell
compar
nonfunction
nanoparticl
apart
encapsul
sever
strategi
exploit
codeliveri
antigen
nanoparticl
surfac
absorpt
conjug
mixtur
refer
fig
nevagi
et
al
observ
enhanc
immun
activ
ga
group
streptococcu
antigen
use
trimethyl
chitosan
tmc
nanoparticl
conjug
b
cell
cell
epitop
compar
antigen
mix
tmc
nanoparticl
also
shown
potenti
use
adjuv
immunomodul
activ
inflammasom
activ
complement
system
activ
recruit
immun
cell
due
abovement
effect
nanoparticl
act
better
adjuv
comparison
complet
freund
adjuv
convent
aluminum
contain
salt
induc
higher
immunogen
respons
low
antigen
dose
also
small
size
facilit
intern
dendrit
cell
induc
adapt
immun
respons
studi
swaminathan
et
al
prove
enhanc
immun
respons
lipid
nanoparticl
lnp
adjuv
formul
ovalbumin
ova
hepat
b
viru
surfac
antigen
hbsag
balbc
mice
inject
hbsag
along
lnp
compar
hbsag
alon
coadministr
quartern
chitosan
nanoparticl
adjuv
along
ovalbumin
intranas
femal
balbc
mice
induc
activ
apc
follow
enhanc
lymphocyt
prolifer
differenti
compar
ova
mix
aluminum
hydroxid
gel
asgari
et
al
also
report
silver
nanoparticl
show
increas
antibodymedi
respons
rabi
reduc
toxic
compar
convent
use
adjuv
alum
although
nanoparticl
possess
great
adjuv
properti
codeliveri
along
gener
use
adjuv
tlr
agonist
provid
robust
immun
protect
use
tlr
agonist
restrict
instabl
particularli
use
rna
tlr
agonist
nugyen
et
al
design
lipidoid
effect
deliv
immunostimulatori
rna
activ
innat
adapt
immun
respons
lipidrna
nanoparticl
enhanc
respons
antiova
cellmedi
antibodymedi
respons
lipidoid
superior
convent
use
n
propyl
n
n
ntrimethyl
ammonium
methyl
sulfaterna
deliveri
system
similarli
unmethyl
cpgrich
oligodeoxynucleotid
cpg
tlr
agonist
nanoparticl
induc
pro
inflammatori
respons
antigenspecif
antibodi
cellmedi
immun
coloc
mpla
cpg
also
induc
function
memori
cell
find
clearli
demonstr
abil
bacteri
element
tlr
agonist
toward
develop
effect
vaccin
design
addit
tlr
agonist
use
design
diseasespecif
nanovaccin
discuss
later
review
layer
layer
protein
nanoclust
synthes
recombin
trimer
hemagglutinin
immunogen
induc
protect
antibodymedi
respons
without
use
adjuv
high
immunogen
potenti
peptid
nanoclust
high
antigen
densiti
avail
surfac
nanoparticl
variou
type
nanoparticl
use
nanovaccin
formul
type
serv
differ
function
elabor
next
section
proteinbas
nanovaccin
serv
structur
well
function
purpos
carri
antigen
engag
pattern
recognit
receptor
apc
proteinbas
nanovaccin
categor
biomimet
viruslik
particl
cage
vault
ration
design
nanofibril
selfassembl
protein
nanoparticl
nanoclust
micel
biomimet
proteinbas
nanovaccin
biomimet
proteinbas
nanovaccin
viral
origin
selfassembl
viral
capsid
protein
devoid
genet
materi
categor
viruslik
particl
vlp
refer
fig
e
hand
prokaryot
eukaryot
origin
call
protein
cage
vault
cage
vault
gener
use
biocatalysi
molecular
transport
share
common
properti
vlp
like
nanoscal
symmetri
contain
like
geometri
structur
modifi
chemic
biolog
antigen
immun
activ
vlp
nm
salmonella
typhimurium
bacteriophag
engin
encapsul
two
respiratori
syncyti
viru
rsv
protein
antigen
matrix
matrix
mice
vaccin
intranas
boost
show
antigenspecif
cell
respons
upon
subsequ
rsv
challeng
reduct
viral
load
increas
antigenspecif
cell
observ
lung
vaccin
mice
compar
empti
vaccin
unvaccin
anim
cage
like
nm
cage
deriv
pyruv
dehydrogenas
complex
bacillu
stearothermophilu
nm
cage
human
heavi
chain
ferritin
iron
storag
protein
nm
encapsulin
class
icosahedr
cage
structur
bacteria
archaea
use
present
differ
antigen
elicit
immun
respons
immun
recent
studi
nonvir
proteinbas
biomimet
nanoparticlecontain
acidlabil
cpg
dc
activ
molecul
siinfekl
peptid
epitop
conjug
shown
potenti
enhanc
cpg
mediat
dc
activ
vitro
compar
unbound
cpg
interestingli
codeliveri
siinfekl
peptid
conjug
cpg
shown
elev
crosspresent
cell
activ
induc
greater
display
siinfekl
mhci
dc
compar
unbound
peptid
peptid
bound
directli
protein
show
abil
biomimet
proteinbas
nanoparticl
facilit
enhanc
immun
respons
dc
activ
crosspresent
vault
eukaryot
ribonucleoprotein
assembl
cagelik
barrelshap
structur
approxim
nm
nm
nm
made
major
vault
protein
mvp
shown
increas
antigenspecif
cell
respons
reduct
genit
bacteri
load
inflamm
observ
chlamydia
muridarum
polymorph
membran
protein
pmpg
encapsul
vault
administ
intranas
ration
design
proteinbas
nanovaccin
nanofibril
gener
made
engin
coil
coil
nanofibril
form
peptid
sequenc
like
qqkfqfqfeqq
fkfefkf
append
c
terminu
peptid
antigen
short
linker
sequenc
refer
fig
similarli
coiledcoil
also
form
fibril
peptidelik
peptid
sequenc
undergo
assembl
fibril
antigen
epitop
stick
outward
fibril
surfac
fibril
assembl
variou
epitop
plasmodium
falciparum
mycobacterium
tuberculosi
streptococcu
aureu
thelper
cell
epitop
padr
ova
epitop
conjug
immunogen
epitop
chikungunya
viru
glycoprotein
selfadjuv
amyloid
assembl
show
cytocompat
enhanc
macrophag
uptak
robust
igg
respons
epitop
selfassembl
protein
nanoparticl
sapn
nm
icosahedron
contain
pentamer
trimer
helic
coiledcoil
conjug
glycin
linker
refer
fig
f
antigen
adjuv
insert
depend
expect
structur
silico
model
subunit
malaria
hiv
toxoplasma
sever
acut
respiratori
syndrom
wahom
et
al
encapsul
two
hiv
protein
epitop
onto
sapn
surfac
observ
enhanc
product
epitopespecif
neutral
antibodi
indic
potenti
sapn
nanovaccin
activ
immun
respons
hiv
nanoclust
also
emerg
promin
vaccin
platform
prepar
desolv
protein
peptid
gener
made
antigen
crosslink
intent
increas
antigen
load
elimin
offtarget
sequenc
intranas
vaccin
influenza
matrix
protein
contain
selfassembl
protein
nanoclust
elicit
enhanc
immun
respons
complet
protect
lethal
challeng
hetero
homosubtyp
viru
sinc
prepar
nanoclust
requir
organ
solvent
may
alter
secondari
quaternari
structur
full
protein
antigen
micel
antigen
molecul
conjug
micel
two
differ
way
either
coval
link
onto
micellar
surfac
conjug
varieti
alkyl
tail
form
amphiphil
peptid
micel
pam
micel
differ
size
shape
affect
immun
activ
potenti
studi
shown
cylindr
spheric
pam
effici
abl
reach
lymph
node
carri
requir
amount
antigen
adjuv
studi
report
pam
mediat
increas
immunogen
cell
b
cell
epitop
peptid
lipid
conjug
also
form
nanodisc
vaccin
refer
fig
g
subcutan
vaccin
neoantigen
adpgk
nanodisc
show
enhanc
cellular
respons
apc
uptak
increas
surviv
melanoma
challeng
compar
intramuscular
vaccin
peptidepolymer
micel
also
explor
vaccin
platform
conjug
hydrophil
peptid
antigen
dendrim
polym
immunotherapi
common
lipidbas
nanovaccin
get
explor
past
decad
liposom
nanovaccin
refer
fig
b
offer
distinct
advantag
nanovaccin
system
term
biodegrad
toler
less
immunogen
tunabl
physicochem
properti
provid
wide
repertoir
load
antigen
differ
philic
insid
outsid
liposom
easi
surfac
conjug
differ
physicochem
properti
like
size
surfac
charg
surfac
modif
peg
bilay
composit
fluiditi
affect
immunolog
outcom
liposom
nanovaccin
sizedepend
differenti
activ
immun
respons
indic
activ
respons
nm
size
liposom
compar
respons
liposom
nm
transderm
immun
mice
dissolv
microneedl
load
opposit
charg
transferosom
indic
enhanc
immun
respons
cation
transferosom
compar
anion
counterpart
exhibit
strong
endocyt
escap
properti
fecilit
antigen
process
via
mhci
pathway
larger
accumul
lymph
node
kaur
et
al
show
effect
bilay
fluiditi
immun
activ
vari
cholesterol
concentr
rel
lesser
vivo
igg
product
observ
liposom
formul
contain
high
cholesterol
similarli
effect
anoth
import
factor
affect
bilay
fluiditi
liposom
mediat
immun
activ
observ
prepar
liposom
phospholipid
differ
transit
temperatur
tm
high
tm
phospholipid
contain
liposom
stimul
immun
respons
compar
low
tm
phospholipid
induc
respons
mice
immun
leishmaniasi
antigen
numer
clinic
studi
show
use
liposom
adjuv
therapeut
vaccin
liposom
encapsul
pteronyssinu
vaccin
reduc
allergen
bronchial
provoc
induc
inflammatori
chang
improv
condit
asthma
patient
sustain
mite
exposur
phase
iii
studi
tecetomid
vaccin
contain
blp
lipopeptid
antigen
incorpor
dmpg
dppc
chol
mplliposom
perform
stage
iii
nonsmal
cell
lung
cancer
subcutan
immun
howev
studi
termin
due
effect
surviv
primari
secondari
endpoint
phase
ii
studi
phase
trial
show
safeti
immunogen
liposom
adjuv
system
given
subunit
vaccin
tuberculosi
antigen
adjuv
vaccin
show
longlast
cell
respons
antibodi
respons
observ
healthi
adult
viral
liposom
call
virosom
also
studi
literatur
virosom
exhibit
viral
capsid
protein
onto
li
posom
surfac
effect
fuse
target
cell
membran
recent
virosom
liposom
mediat
immun
respons
investig
human
respiratori
tract
tripl
cultur
model
virosom
liposom
prepar
neutral
phospholipid
dopc
pope
virosom
also
fuse
influenza
membran
protein
result
show
enhanc
intern
virosom
epitheli
cell
tripl
cultur
compar
liposom
similar
size
recent
studi
shown
use
lipidbas
nm
particl
iscomatrix
particl
adjuv
chimera
peptid
vaccin
contain
tax
gag
epitop
human
cell
lymphotrop
viru
type
given
subcutan
mice
enhanc
product
mucos
iga
antibodi
titer
along
cytokin
observ
compar
vaccin
formul
anoth
class
lipidbas
nanocarri
includ
hexosom
cubosom
provid
high
membran
surfac
area
antigen
membran
protein
load
hexosom
gener
made
lipid
known
form
nonlamellar
structur
hydrat
system
invers
hexagon
liquid
crystallin
phase
compar
adjuv
activ
mono
mycoloyl
immunopotenti
contain
hexosom
cation
liposom
load
chlamydia
trachomati
major
outer
membran
protein
momp
antigen
mice
vaccin
studi
rodrigu
et
al
hexosom
made
lipid
phytantriol
induc
strong
mompspecif
antibodymedi
immun
respons
wherea
cation
liposom
elicit
much
stronger
mompspecif
cellmedi
respons
indic
immun
activ
two
lipidbas
adjuv
via
differ
mechan
addit
cubosom
gener
made
lipid
bilay
form
continu
period
cubic
lattic
structur
interwoven
water
channel
stabil
polymer
outer
corona
phytantriol
pluron
propylen
glycolbas
cubosom
formul
contain
imiquimod
monophosphoryl
lipid
mpl
adjuv
model
ova
antigen
elicit
robust
product
cell
prolifer
compar
similar
adjuv
contain
liposom
formul
alum
lipidbas
selfassembl
structur
provid
high
antigen
adjuv
load
enhanc
immunoactiv
comparison
convent
lipidbas
carrier
like
liposom
polymer
particl
show
great
possibl
use
nanovaccin
due
eas
prepar
biocompat
biodegrad
finetun
surfac
properti
control
releas
kinet
refer
fig
commonli
use
polymer
nanoparticl
antigen
deliveri
poli
lacticcoglycol
acid
plga
poli
lactic
acid
pla
use
deliv
broad
rang
antigen
like
hepat
b
viru
antigen
tetanu
toxoid
bacillu
anthraci
antigen
mycobacterium
tuberculosi
antigen
ovalbumin
natur
polym
like
chitosan
algin
pullulan
inulin
also
use
adjuv
antigen
carrier
chitosan
alginatebas
nanovaccin
hepat
b
viru
dnabas
chitosan
vaccin
mycobacterium
tuberculosi
mtb
show
mark
increas
immunolog
protect
efficaci
immun
mice
hyperbranch
polyglycerol
hbpg
globular
polym
potenti
candid
inert
dendrim
base
multival
vaccin
coupl
b
cell
epitop
tumorassoci
antigen
cell
epitop
tetanu
toxin
show
enhanc
immun
respons
igg
antibodi
breast
cancer
cell
henc
polymer
nanoparticl
use
potenti
multival
vaccin
sever
inorgan
nanoparticl
gold
iron
carbon
silica
nanoparticl
explor
vaccin
deliveri
differ
diseas
model
refer
fig
c
eas
antigen
function
onto
easili
access
surfac
group
robust
properti
reproduc
outweigh
low
biodegrad
give
edg
use
nanovaccin
also
increas
antigen
stabil
prevent
prematur
proteolyt
degrad
howev
report
show
dose
sizedepend
clinic
toxic
nanoparticl
amongst
inorgan
nanoparticl
gold
nanoparticl
gain
maximum
attent
vaccin
deliveri
particl
use
epitop
deliveri
hiv
influenza
malaria
tumor
effect
shape
gold
nanovaccin
antibodi
product
wnv
envelop
e
protein
show
rod
induc
antibodi
respons
compar
spheric
nanoparticl
multicopi
multival
nanoglycoconjug
gold
nanoparticl
decor
tnantigen
glycan
gener
strong
longlast
antibodi
breast
cancer
express
aberr
mucin
glycan
inorgan
carbon
spheric
nanoparticl
nanotub
use
adjuv
increas
immunogen
act
deliveri
vehicl
peptid
protein
variou
viral
infect
oral
immun
bovin
serum
albumin
bsa
load
carbon
nanoparticl
show
effect
stimul
mucos
iga
antibodi
intestin
vagin
salivari
mucosa
along
respons
abund
silanol
group
silica
nanoparticl
surfac
provid
advantag
easi
conjug
target
moieti
variou
viral
infect
silica
vesicl
adsorb
glycoprotein
bovin
viral
diarrhea
viru
bvdv
show
antibodymedi
cellmedi
immun
respons
histopatholog
chang
site
infect
use
magnet
iron
oxid
nanoparticl
tumorassoci
carbohydr
antigen
taca
phospholipid
function
taca
glycopeptid
show
enhanc
antibodi
titer
human
mous
tumor
cell
express
glycopeptid
calcium
nanoparticl
also
report
superior
adjuv
properti
dna
vaccin
confer
mucos
immun
also
induc
enhanc
antibodi
product
viral
antigen
compar
aluminum
adjuv
sinc
differ
type
nanoparticl
impart
differ
properti
develop
nanovaccin
vast
use
immun
activ
varieti
antigen
observ
though
clear
demarc
direct
comparison
across
nanocarri
studi
uniqu
properti
advantag
associ
nanocarri
give
edg
biomimet
carrier
like
vlp
expect
possess
inher
immunogen
elicit
antibodi
reaction
carrier
antigen
could
lead
competit
target
antigen
alter
antibodi
repertoir
memori
respons
reactiv
toxic
neutral
upon
repeat
dose
also
limit
multipl
use
patient
problem
avoid
use
nanoclust
sole
made
singl
type
antigen
proteinbas
biomimet
ration
design
nanocarri
suitabl
incorpor
highli
hydrophob
antigen
vari
size
intent
preserv
nativ
structur
wherea
hydrophil
peptid
well
deliv
use
amphiphil
micel
carrier
specif
immun
respons
also
observ
certain
polymer
lipidbas
carrier
avoid
use
natur
biomimet
compon
eg
cellular
lipid
isol
extracellular
matrix
polym
control
spatiotempo
tabl
differ
type
nanovaccin
escal
immunogen
potenti
antigen
boost
immunogen
respons
memori
gener
antigen
low
dose
immunogen
respons
gener
certain
antigen
use
two
differ
scenario
vari
use
vaccin
prophylact
therapeut
refer
fig
prophylact
vaccin
aim
develop
protect
immun
administ
onset
diseas
goal
prophylact
vaccin
develop
immunogen
memori
certain
infect
major
challeng
prophylaxi
obtain
suffici
longlast
immunogen
memori
instanc
singledos
immun
mice
polyanhydrid
nanoparticl
contain
pneumococc
surfac
protein
pspa
virul
factor
pneumonia
activ
protect
immun
enhanc
surviv
anim
upon
challeng
even
reduct
dose
pspa
base
nanovaccin
formul
perform
compar
protein
adjuv
alum
much
less
tissu
reactiv
site
immun
prophylact
nanovaccin
confer
protect
immun
mostli
infecti
condit
low
dose
immunostimul
antigen
reduc
need
adjuv
thu
mitig
associ
toxic
therapeut
vaccin
administ
onset
diseas
alter
cours
diseas
encourag
immun
system
fight
harder
prevail
condit
uniqu
immun
respons
gener
diseasespecif
antigen
gener
therapeut
vaccin
use
cancer
treatment
compel
evid
suggest
potenti
use
autoimmun
disord
also
advantag
use
therapeut
vaccin
instead
convent
pharmaceut
treatment
lie
specif
monospecif
diseas
phase
ii
relev
pmhc
complex
coat
nanoparticl
surfac
trigger
select
expans
memorylik
autoregulatori
cell
aris
affect
individu
engin
nanoparticl
potenti
becom
suitabl
vaccin
capac
resolv
organ
diseasespecif
autoimmun
respons
system
deliveri
typei
diabet
relev
peptidemhcnanoparticl
complex
trigger
expans
memori
autoregulatori
cell
suppress
autoimmun
attack
insulinproduc
beta
cell
thu
restor
glucos
balanc
certain
case
nanovaccin
formul
achiev
prophylact
therapeut
respons
poli
glutam
acid
base
synthet
vaccin
nanoparticl
svnp
load
ovalbumin
tolllik
receptor
agonist
poli
c
synthes
kim
et
al
enhanc
uptak
antigen
apc
enhanc
secret
inflammatori
cytokin
type
interferon
simultan
inject
svnpova
svnpic
confer
protect
well
therapeut
immun
inhibit
tumor
growth
tumorbear
mice
clear
abovement
exampl
nanovaccin
modul
immun
system
either
provid
prophylaxi
therapeut
respons
patholog
condit
majorli
prophylact
vaccin
use
prevent
infect
tabl
therapeut
vaccin
use
cancer
tabl
treatment
infect
prevent
vaccin
still
contribut
approxim
half
child
morbid
year
treatment
immun
infecti
condit
greater
challeng
due
rapid
emerg
new
pathogen
variant
spite
advanc
vaccin
develop
year
mani
vaccin
associ
risk
regain
pathogen
certain
immunocompromis
condit
imper
need
develop
riskfre
effect
vaccin
confer
desir
antibodymedi
cellmedi
immun
infecti
diseas
subunit
nanovaccin
enterohemorrhag
escherichia
coli
ehec
develop
use
gold
nanoparticl
conjug
ehec
antigen
induc
high
titer
serum
igg
upon
subcutan
administr
mice
also
prevent
colon
ehec
cecum
larg
intestin
day
postimmun
mice
immun
anthrax
singl
dose
plgabas
protect
antigen
domain
nanoparticl
elicit
robust
antibodymedi
cellmedi
respons
mix
subtyp
respons
surviv
rate
mice
immun
immun
mice
lethal
challeng
bacillu
anthraci
spore
nanovaccin
also
shown
great
prospect
mitig
parasit
invas
chimer
peptid
contain
leishmania
infantum
epitop
histon
kinetoplastid
membran
protein
cystein
peptidas
encapsul
plga
nanoparticl
stimul
peptidebas
nanovaccin
induc
matur
dc
product
subsequ
promot
allogen
cell
prolifer
product
cell
immun
transgen
mice
peptidebas
nanovaccin
induc
peptidespecif
produc
cell
confer
protect
l
infantum
infect
multipl
selfassembl
peptidebas
nanovaccin
contain
epitop
toxoplasma
gondii
specif
antigen
design
immun
selfassembl
protein
nanoparticl
activ
cell
produc
protect
transgen
mice
subsequ
challeng
type
ii
parasit
exampl
nanovaccin
highli
preval
infecti
diseas
discuss
detail
tuberculosi
deadliest
infecti
diseas
greatest
caus
mortal
worldwid
infect
individu
develop
diseas
within
one
two
year
infect
rest
develop
diseas
later
stage
life
immun
function
compromis
coinfect
hiv
patient
mtb
mycobacterium
tuberculosi
complic
situat
mortal
year
bcg
bacil
calmetteguerin
wide
accept
vaccin
tb
tuberculosi
protect
efficaci
limit
age
due
absenc
consensu
genom
loci
present
virul
strain
mtb
induc
short
term
variabl
immun
respons
urgent
requir
booster
vaccin
augment
cell
immun
lung
bcgvaccin
individu
address
ansari
et
al
synthes
archeosom
encapsul
cell
antigen
upon
immun
elicit
cytokin
respons
mice
also
increas
product
antibodi
antigenspecif
lymphocyt
enhanc
jid
actbio
april
express
costimulatori
molecul
surfac
apc
virtu
properti
vaccin
archeosom
contain
antigen
reduc
mycobacteri
burden
lung
spleen
anim
upon
challeng
mtb
similarli
selfassembl
peptid
nanofib
load
cell
epitop
also
show
similar
respons
induc
correspond
effector
memori
cell
increas
cytotox
cell
popul
lung
upon
intranas
immun
mice
vaccin
coassembl
nanofib
contain
cell
epitop
agonist
lung
increas
expans
multifunct
cytotox
cell
popul
challeng
mtb
signific
reduct
lung
bacteri
load
observ
comparison
bcg
prime
mice
anoth
studi
mtb
lipidbas
nanovaccin
use
wherein
chitosan
nanoparticl
bound
mtb
lipid
induc
cellmedi
antibodymedi
immun
secret
immunoglobulin
igg
igm
promin
cytokin
lymph
node
spleen
cell
higher
potenc
nanoparticl
encapsul
antigen
prepar
abil
form
depot
slow
steadi
releas
surround
milieu
enhanc
uptak
antigen
antigenpres
cell
shown
studi
diogo
et
al
liposomeencapsul
antigen
elicit
profound
antibodymedi
cellmedi
respons
free
antigen
mice
immun
free
antigen
liposomeencapsul
antigen
challeng
mice
week
post
immun
mtb
observ
mtb
burden
lung
spleen
significantli
less
mice
immun
liposomeencapsul
antigen
compar
free
bcg
vaccin
potenti
nanoparticl
augment
prophylact
activ
antigen
tb
well
understood
human
trial
initi
firstinman
trial
novel
liposom
adjuv
along
tuberculosi
vaccin
report
human
volunt
vaccin
escal
dose
week
immun
strong
antigenspecif
cell
respons
persist
week
caus
local
system
advers
effect
discuss
preclin
clinic
assess
variou
antigenload
nanoparticl
indic
potenti
nanovaccin
induc
robust
longlast
cellular
immun
mtb
show
hope
develop
differ
effect
prophylact
regim
tb
clear
advent
nanotechnolog
adjuv
deliveri
vehicl
associ
problem
reduc
effect
host
environ
lack
consensu
genet
loci
still
remain
inevit
challeng
develop
effici
vaccin
tb
malaria
known
affect
almost
million
peopl
annual
half
million
death
worldwid
fight
malaria
challeng
multistag
life
cycl
variou
effort
made
design
vaccin
preerythrocyt
blood
stage
malaria
similarli
nanovaccin
use
target
multipl
stage
malaria
iron
oxid
io
nanoparticl
use
deliveri
merozoit
surfac
protein
immun
mice
load
nanoparticl
induc
parasit
inhibitori
antibodi
high
titer
macrophag
dendrit
cell
show
intern
io
nanoparticl
enhanc
express
cytokin
chemokin
immun
respons
gener
sexual
stage
antigen
malaria
impair
transmiss
reduc
diseas
burden
one
malaria
transmissionblock
vaccin
antigen
immunogen
limit
human
henc
use
along
nanoformul
achiev
desir
immun
respons
exampl
codon
harmon
use
gold
nanoparticl
adjuv
induct
immun
transmiss
strong
transmissionblock
antibodi
elicit
simultan
deliveri
gold
nanoparticl
could
due
coingest
nanoparticl
antigen
immun
cell
similarli
recombin
polyhistidinetag
histag
mix
preform
coporphyrin
contain
liposom
time
immun
result
spontan
nanoliposom
antigen
particular
snap
immun
mice
rabbit
snap
result
higher
function
antibodi
gener
compar
mixandinject
adjuv
also
use
develop
multiantigen
vaccin
apic
membran
nanp
peptid
target
multipl
stage
plasmodium
life
cycl
use
liposom
ovalbumin
load
carboxyl
polystyren
nanoparticl
act
adjuv
induc
granulocyt
colonystimul
factor
affect
migratori
home
abil
dendrit
cell
mice
challeng
malaria
two
week
immun
nanoparticl
produc
antimalaria
antibodi
creat
state
immun
readi
subsequ
infecti
challeng
stabl
nanomim
polymersom
receptor
parasit
attach
synthes
bind
host
cell
block
reinvas
parasit
releas
host
cell
vitro
strategi
use
futur
modul
immun
respons
malaria
effici
design
vaccin
thu
increas
role
nanovaccin
target
multipl
life
cycl
stage
malaria
show
new
avenu
build
robust
vaccin
regim
prevent
malaria
infect
three
type
influenza
virus
b
c
differ
viral
nucleoprotein
matrix
protein
give
rise
variabl
antigen
differ
among
influenza
viru
b
caus
epidem
attack
adult
children
caus
around
million
infect
annual
present
two
type
vaccin
use
influenza
base
strain
strain
b
target
produc
antibodymedi
protect
respons
hemagglutinin
neuraminidas
antigen
highli
prone
antigen
shift
drift
due
errorpron
rna
depend
rna
replic
influenza
due
environment
select
antigen
variat
chanc
influenza
epidem
still
persist
although
anim
influenza
viru
distinct
human
viru
zoonot
anim
virus
still
occasion
infect
human
directindirect
contact
avian
swine
influenza
virus
known
infect
human
countri
thu
unmet
need
produc
effici
vaccin
provid
antibodymedi
cellmedi
immun
confront
homolog
heterolog
variant
associ
variou
influenza
antigen
nanoparticl
shown
promis
preliminari
result
provid
enhanc
immun
respons
variabl
influenza
antigen
antigen
variabl
limit
use
singl
vaccin
influenza
viru
iav
effort
develop
nanovaccin
confer
protect
one
serotyp
use
conserv
ectodomain
influenza
matrix
protein
nanoparticl
contain
selfassembl
recombin
cage
human
heavi
chain
ferritin
present
repeat
protein
observ
elicit
elev
level
igg
mucos
secretori
iga
antibodi
enhanc
cell
respons
lethal
infect
intranas
administr
mice
nanovaccin
conserv
ectodomain
confer
protect
interspeci
viral
infect
selfassembl
viruslik
particl
vlp
contain
multipl
copi
protein
insert
capsid
cap
protein
porcin
circoviru
type
shown
dual
protect
iav
lethal
challeng
mice
pig
gener
specif
neutral
antibodi
hemagglutinin
trimer
also
exploit
potenti
antigen
induc
protect
immun
influenza
viru
pham
et
al
immun
balbc
mice
nanodiamond
conjug
trimer
observ
signific
higher
specif
igg
product
compar
immun
trimer
antigen
alon
similarli
ross
et
al
shown
intranas
subcutan
immun
balbc
mice
polyanhydrid
nanoparticl
encapsul
induc
high
titer
neutral
antibodi
also
significantli
higher
cell
expans
observ
vaccin
mice
compar
nonvaccin
mice
thu
provid
cellmedi
antibodymedi
protect
immun
mice
mice
challeng
intranas
influenza
viru
day
post
immun
viral
load
significantli
reduc
compar
salineadminist
mice
also
demonstr
polyanhydrid
nanoparticl
give
equival
respons
lower
dose
compar
free
antigen
also
encapsul
antigen
polyanhydrid
nanovaccin
exhibit
stabil
antigen
one
year
room
temperatur
thu
provid
major
benefit
maintain
stock
pandem
vaccin
discuss
nanovaccin
design
variou
research
group
combin
nanomateri
differ
antigen
provid
protect
particular
strain
viru
due
antigen
variat
multipl
strain
influenza
viru
emerg
year
pose
seriou
public
threat
indic
need
univers
vaccin
includ
broad
crosspresent
multipl
strain
influenza
reduc
commun
threat
insight
structur
properti
antigen
peptid
explor
ration
design
broadspectrum
nanovaccin
use
multipl
antigen
similar
line
increas
breadth
potenc
nanovaccin
deng
et
al
design
doublelay
protein
nanoparticl
core
protein
nanoparticl
contain
four
type
human
swine
avian
domest
fowl
viral
consensu
sequenc
coat
ha
variant
refer
fig
mice
immun
intramuscularli
pnp
doublelay
pnp
doublelay
pnp
cocktail
robust
antibodymedi
respons
gener
induc
antibodi
strongli
crossreact
divers
antigen
also
group
produc
broad
cellular
respons
significantli
induc
secret
splenocyt
stimul
divers
antigen
peptid
mice
vaccin
sera
preimmun
mice
dpb
challeng
intranas
aic
hour
sera
immun
mice
prevent
mice
viral
infect
indic
role
serum
antibodi
also
antibodi
specif
human
aic
viabl
four
month
immun
mice
impli
longlast
protect
exampl
discuss
evid
help
structur
import
antigen
smartli
design
protein
nanomateri
potenti
induc
longlast
immun
broad
spectrum
antigen
thu
provid
platform
produc
effici
nanovaccin
combat
pandem
virus
hiv
sixth
lead
caus
death
worldwid
hiv
infect
caus
system
deplet
cell
henc
compromis
activ
immun
system
develop
aid
immun
function
preserv
earli
stage
hiv
use
antiretrovir
therapi
art
target
hiv
life
cycl
major
challeng
strict
adher
complex
art
regimen
necessit
urgent
need
develop
prophylact
vaccin
hiv
recent
promis
hiv
vaccin
phase
iii
trial
igg
antibodi
rais
loop
invers
correl
risk
infect
clinic
trial
sapnbas
vaccin
reduc
need
essenti
glycosyl
env
loop
form
nativelik
structur
act
potenti
immunogen
although
selfassembl
vlp
vector
shown
great
potenti
develop
immun
hiv
antivector
immun
signific
concern
synthet
nanoparticl
offer
versatil
platform
technolog
induc
strong
adapt
immun
respons
avoid
anti
vector
immun
toxic
issu
plga
base
nanoparticl
use
coutil
tlr
agonist
antigen
intraderm
immun
mice
antigenagonistnanoparticl
enhanc
igg
product
even
lesser
dose
antigen
nanovaccin
shift
immun
respons
toward
polar
enhanc
cytokin
pattern
recent
proteas
cleavag
site
pc
util
strategi
hamper
matur
infect
hiv
due
low
immunogen
peptid
antigen
crosslink
chitosan
hyaluron
base
nanoformul
nanoparticl
contain
pc
show
enhanc
activ
apc
product
antipc
antibodi
also
nanoparticl
gener
memori
cell
longer
time
point
last
booster
dose
indic
capac
elicit
good
immun
respons
upon
infect
silver
nanoparticl
coat
amantadin
trigger
product
hiv
specif
ctl
spleen
mice
stronger
product
vivo
cocultur
hiv
specif
ctl
hiv
infect
cell
vitro
enhanc
death
infect
cell
reduc
product
hiv
similarli
peptid
oligosaccharid
load
aunp
enhanc
antigen
present
isol
cell
patient
treatment
aunp
formul
vaccin
increas
prolifer
hivspecif
cell
increas
secret
cytokin
proinflammatori
cytokin
vitro
malik
et
al
shown
prophylact
potenti
intravagin
deliv
nanogold
load
formul
poloxom
hyaluron
base
thermogel
load
gold
niosom
mannosyl
gold
niosom
along
efavirenz
efv
efv
gnp
inhibit
viral
dissemin
pbmc
peripher
blood
mononuclear
cell
host
cell
individu
potenti
inhibit
preinteract
viral
dissemin
lower
combin
substanti
increas
activ
seen
efv
given
gnp
moieti
dualfac
attack
wherein
gnp
inhibit
hiv
entri
cell
caus
denatur
glycoprotein
efv
inhibit
transcriptas
enzym
mannosyl
efvgnp
man
egnz
show
potenti
activ
inhibit
viral
dissemin
host
preexpos
viral
infect
thermogel
contain
efvgnp
man
egnz
show
inhibit
respect
antigen
antihiv
prophylact
challeng
studi
variou
formul
develop
year
enhanc
prophylact
action
raltegravir
efavir
phthalat
efavirenz
efavirenz
saquinavir
bayon
et
al
also
shown
capac
nanolipid
complex
nlc
induc
specif
immun
respons
hiv
nonhuman
primat
nhp
four
intraderm
immun
period
month
show
nlcload
antigen
elicit
significantli
higher
antibodi
compar
combin
free
antigen
cpg
adjuv
advanc
understand
role
nanovaccin
fight
hiv
develop
nanovaccin
load
formul
prophylaxi
hiv
emerg
use
nanotechnolog
develop
effici
vaccin
system
hiv
prevent
far
despit
constant
effort
develop
effect
cancer
vaccin
efficaci
clinic
alway
limit
nonetheless
two
prophylact
vaccin
hepat
b
virusassoci
liver
cancer
human
papillomaviru
virusassoci
cervic
cancer
approv
us
fda
till
prophylact
vaccin
develop
cancer
erad
challeng
due
ineffici
identif
tumorspecif
antigen
neoantigen
rapid
clearanc
less
accumul
lymphoid
organ
gener
weak
memori
immun
respons
therefor
use
nanoparticl
overcom
limit
would
advantag
strategi
prolong
sustain
deliveri
antigen
would
extrem
import
gener
immunolog
memori
booster
dose
reduct
immun
mice
protein
nanoparticl
conjug
melanomaassoci
epitop
cpg
adjuv
enhanc
product
melanomaspecif
cell
preimmun
nanoparticl
delay
onset
tumor
growth
increas
surviv
rate
show
prophylact
potenti
protein
nanoparticl
luo
et
al
show
strong
cytotox
cell
respons
physic
mixtur
polymer
nanoparticl
ova
antigen
achiev
enhanc
cytosol
deliveri
antigen
present
apc
drain
lymph
node
np
activ
typei
interferon
stimul
gene
nanovaccin
show
tumor
growth
inhibit
melanoma
human
papilloma
viru
tumor
colon
cancer
model
combin
np
show
synerg
surviv
model
day
rechalleng
tumorfre
mice
cell
immun
nanoparticl
show
complet
tumor
growth
inhibit
indic
prophylact
respons
nanovaccin
gener
longterm
antitumor
memori
liu
et
al
develop
uniqu
prophylact
nanovaccin
use
metalloorgan
nanoparticl
mof
coat
fuse
membran
fm
dendrit
cell
cancer
cell
presenc
whole
tumor
antigen
immunolog
costimulatori
molecul
cytomembran
impart
apc
like
properti
cancer
specif
cell
immunoactiv
sinc
fusion
dc
cancer
membran
accompani
dc
matur
mof
fm
nanovaccin
possess
lymph
node
home
molecul
therefor
enhanc
retent
home
mof
fm
lymph
node
spleen
compar
cancer
membran
fuse
mof
cm
dendrit
cell
membran
fuse
mof
dm
nanovaccin
observ
preimmun
mice
mof
fm
significantli
prevent
develop
tumor
promot
differenti
cell
precursor
cytotox
cell
enhanc
gener
immunostimulatori
cytokin
refer
fig
tumor
heterogen
differenti
express
antigen
make
challeng
develop
prophylact
treatment
strategi
therefor
nanovaccin
develop
cancer
therapeut
detail
descript
given
next
section
unlik
convent
therapeut
therapeut
nanovaccin
offer
prospect
elicit
antigenspecif
respons
without
addit
nonspecif
respons
therapeut
vaccin
use
autoimmun
disord
antigenspecif
target
tregulatori
cell
clinic
studi
reveal
therapeut
efficaci
vlp
allergeninduc
asthma
bacteriophag
deriv
vlp
pack
cpg
tlr
induc
respons
immun
system
total
asthmat
patient
treat
inject
vlp
part
doubleblind
random
trial
observ
asthma
wellcontrol
patient
treat
vlp
compar
placebo
group
unlik
cancer
nanovaccin
show
promis
result
pathogen
infect
presenc
extrem
potent
foreign
nonself
antigen
therefor
vaccinebas
therapi
still
limit
cancer
treatment
provid
altern
complement
convent
cancer
treatment
till
cancer
vaccin
fail
make
mark
clinic
compar
immunotherapi
like
cell
therapi
checkpoint
blockad
us
fda
approv
therapeut
cancer
vaccin
proveng
sipuleucelt
shown
moder
increas
clinic
efficaci
prostat
cancer
major
problem
success
develop
cancer
vaccin
select
tumorspecif
antigen
call
neoantigen
convent
cancer
vaccin
develop
target
tumorassoci
antigen
taa
overexpress
specif
particular
tumor
type
across
patient
howev
taa
also
present
normal
tissu
therefor
vaccin
specif
induc
peripher
central
immunotoler
lead
autoimmun
low
vaccin
effici
neoantigen
tumorspecif
antigen
deriv
random
somat
mutat
absent
normal
cell
henc
vaccin
target
neoantigen
use
nanoparticl
may
enhanc
outcom
cancer
immunotherapi
cancer
nanovaccin
present
uniqu
highli
immunogen
tumorspecif
antigen
increas
antigen
load
effici
deliveri
control
antigen
present
retent
lymphoid
organ
recent
studi
show
target
bone
marrow
splenic
dc
peptid
ty
use
mesopor
silica
nanoparticl
conjug
ovacpg
immun
activ
msntyovacpg
therapeut
applic
msntyovacpg
mice
enhanc
dc
activ
tumor
elimin
elicit
tumorspecif
cell
respons
prolong
surviv
less
system
toxic
overcom
inadequ
load
effici
weak
immun
respons
complex
prepar
process
dong
et
al
prepar
antigen
nanoparticl
ovalbumin
np
contain
cpg
adjuv
onpscpg
high
antigen
adjuv
load
cancer
immunotherapi
vitro
vivo
result
show
enhanc
immun
respons
includ
dc
matur
cell
activ
product
onpscpg
induc
remark
antitumor
efficaci
mous
lymphoma
model
biomimeticapproach
develop
cancer
nanovaccin
overcom
cancer
heterogen
use
patientderiv
cell
membran
develop
smart
nanovaccin
promis
biomimet
approach
person
therapi
variou
strategi
explor
form
develop
artifici
antigenpres
cell
aapc
base
nanovaccin
use
differ
cell
membran
fuse
nanovaccin
membran
coat
virus
enhanc
crosspresent
immun
stimul
refer
fig
recent
kuai
et
al
shown
antitumor
efficaci
highdens
lipoprotein
hdl
nanodisc
load
neoantigen
peptid
cpg
cell
receptor
agonist
colon
carcinoma
model
nanodisc
deliv
neoantigen
drain
lymph
node
enhanc
antigen
present
apc
caus
enhanc
stimul
cytotox
cell
respons
potenti
inhibit
tumor
growth
deliveri
nanodisc
checkpoint
blockad
therapi
also
erad
establish
colon
carcinoma
strategi
show
power
therapi
gener
person
cancer
medicin
zhang
et
al
develop
magnet
artifici
antigenpres
cell
aapc
enhanc
cellmedi
tumorigen
respons
develop
fe
magnet
nanoclust
coat
leucocyt
membran
antigen
decor
mhci
load
peptid
siinfekl
costimulatori
ligand
tumor
biomimet
aapc
stimul
cell
visual
guid
tumor
magnet
caus
reduc
tumor
burden
offer
great
platform
cellbas
immunotherapi
fusion
biolog
membran
nanovaccin
emerg
interest
concept
toward
biomimet
nanovaccin
recent
studi
show
biomimet
cancerderiv
magnetosom
enhanc
retent
lymph
node
subcutan
administr
tolllik
receptor
tlr
agonist
cpg
load
fe
magnet
nanoclust
camouflag
cancer
membran
decor
preferenti
recognit
dc
popul
crosspresent
cell
via
mhci
enhanc
stimul
tumorspecif
cell
due
prolong
retent
magnet
guid
nanoclust
lymph
node
show
antitumor
efficaci
improv
surviv
differ
mice
model
similarli
guo
et
al
develop
erythrocyt
membran
coat
plga
nanoparticlecontain
antigen
peptid
monophosphoryl
lipida
mpla
agonist
enhanc
antitumor
immun
intraderm
inject
shown
reduc
tumor
burden
along
metastasi
prolong
tumor
occur
time
rechalleng
metastat
model
studi
exploit
cancer
cell
membran
envelop
impart
wide
repertoir
cancerspecif
antigen
offer
advantag
develop
variou
person
vaccin
toward
multipl
tumor
type
anoth
interest
strategi
develop
person
biomimet
cancer
nanovaccin
use
cancer
cell
membran
coat
viru
increas
adjuvant
infect
oncolyt
activ
gener
strong
antitumor
immun
respons
recent
studi
show
prophylact
therapeut
potenti
nm
biohybrid
artifici
envelop
viru
extracrad
extra
condit
replic
adenoviru
oncolyt
adenoviru
serotyp
contain
cpg
island
base
pair
delet
encapsul
cancer
cell
line
membran
coat
cancer
membran
found
enhanc
vitro
cytotox
extracrad
compar
nake
viru
indic
enhanc
infect
viral
vaccin
compar
nake
viru
multipl
cell
line
intratumor
inject
extracrad
mice
contain
induc
model
show
vivo
therapeut
vaccin
efficaci
facilit
reduc
tumor
prolifer
compar
nake
viru
individu
vaccin
compon
control
viru
membran
mixtur
enhanc
crosspresent
cell
activ
prophylact
potenti
explor
vaccin
mice
time
vaccin
cell
rechalleng
respect
prolong
overal
surviv
enhanc
inhibit
tumor
prolifer
homolog
membran
envelop
viral
vaccin
group
compar
nake
viru
heterolog
membran
envelop
group
indic
strong
potenti
viralbas
vaccin
impart
wide
repertoir
cancerspecif
antigen
prevent
vaccin
anoth
viral
proteinco
dendrim
nanovaccin
contain
peptid
epitop
hpv
show
enhanc
cytotox
cell
stimul
follow
hpv
infect
cell
erad
tumor
elimin
observ
treat
mice
recurr
month
post
initi
challeng
therefor
address
problem
associ
cancer
vaccin
develop
special
emphasi
given
biomimet
person
nanovaccin
use
apc
nanoparticl
coat
patient
cancer
cell
membran
provid
effect
antigen
divers
overcom
tumor
heterogen
tumorspecif
immun
respons
provid
key
strategi
train
one
immun
system
appropri
antigen
research
use
biomimet
person
approach
significantli
improv
outcom
current
treatment
modal
nanovaccin
shown
potenti
augment
therapeut
prophylact
efficaci
cancer
vaccin
past
decad
research
vaccin
taken
big
leap
forward
explor
vast
potenti
combat
numer
diseas
specif
strong
interact
nanoparticl
immun
system
associ
benefit
attract
atten
tion
hope
produc
less
toxic
effect
nanovaccin
physicochem
variat
nanoparticl
one
prime
factor
affect
fate
nanovaccin
insid
bodi
term
clearanc
specif
bioaccumul
adjuvant
antigen
toxic
potent
antigen
prolong
retent
releas
caus
nanovaccin
elicit
cellmedi
antibodymedi
antibodi
along
memori
effector
respons
thu
allevi
use
frequent
booster
dose
although
nanovaccin
still
infanc
limit
clinic
trial
new
gener
nanovaccin
possess
enorm
potenti
prophylact
therapeut
henc
explor
new
avenu
increas
nanovaccin
safeti
efficaci
drive
forc
research
domain
bionanotechnolog
nanomedicin
toxic
scalingup
process
lack
regulatori
guidelin
consid
limit
factor
product
nanovaccin
nanoscal
size
work
doubl
edg
sword
preclin
clinic
report
show
dosedepend
acut
chronic
toxic
preferenti
bioaccumul
depend
rout
administr
class
nanoparticl
possess
inher
toxic
prolong
exposur
like
inorgan
nanoparticl
eg
metal
nanoparticl
moreov
iscom
use
number
anim
vaccin
toxic
associ
saponinbas
adjuv
prohibit
use
human
therefor
concern
nanoparticl
usag
vaccin
still
exist
scale
anoth
major
problem
minim
extent
technolog
advanc
scaleup
steril
environ
still
signific
challeng
though
convent
treatment
era
modern
medicin
save
countless
live
steadi
rise
antibiot
resist
lack
cur
cancer
therapi
continu
caus
strain
variat
cancer
heterogen
respect
drive
focu
toward
person
therapeut
henc
similar
line
vaccin
bacteri
infect
tumor
could
benefit
significantli
current
vaccin
antigen
breadth
lack
potenc
limit
factor
therefor
research
recent
shift
toward
biomimet
nanotechnolog
develop
biomimet
nanovaccin
person
medicin
nanovaccin
inher
immunostimulatori
multiantigen
coat
bacteri
outer
membran
vesicl
omv
jid
actbio
april
onto
nanoparticl
antivirul
vaccin
deliv
neutral
bacteri
toxin
outplay
pathogen
util
surviv
mechan
prevent
bacteri
colon
effect
reduc
direct
select
pressur
develop
antibiot
resist
larg
number
nanotoxoid
formul
develop
vari
outer
membran
coat
biomimet
nanovaccin
despit
advanc
field
cancer
nanobas
immunotherapi
major
challeng
toxicolog
assess
nanovaccin
prior
evalu
autoimmun
side
effect
gener
nanovaccin
induc
immun
activ
need
done
overactiv
antigen
present
cell
nanovaccin
prove
detriment
may
caus
death
dendrit
cell
last
least
increas
complex
cost
manufactur
commerci
hurdl
relat
nanovaccin
therapi
requir
strategi
minim
limit
success
translat
nanobas
immunotherapi
author
declar
known
compet
financi
interest
person
relationship
could
appear
influenc
work
report
paper
